Last reviewed 2026-04-20 · How we verify

FLOX

Flox, marketed by Hospira, is a therapeutic agent indicated for malignant neoplasm of the liver. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk lies in the lack of reported key trial results and revenue data, which may affect investor confidence and market positioning.

At a glance

Approved indications

• Malignant neoplasm of liver
• Primary malignant neoplasm of gastrointestinal tract

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Enteritis
• Stomatitis
• Localized erythema
• Anemia
• Leukopenia
• Thrombocytopenia
• Elevated alkaline phosphatase
• Elevated serum transaminase
• Elevated serum bilirubin

Serious adverse events

• Arterial thrombosis
• Arterial aneurysm
• Arterial ischemia
• Hepatic necrosis
• Myocardial ischemia
• Embolism
• Thrombophlebitis
• Duodenal ulcer
• Acalculous cholecystitis
• Anaphylaxis

Key clinical trials

• METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (PHASE2)
• METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (PHASE2)
• Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer
• Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
• Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime (NA)
• Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer (PHASE1,PHASE2)
• Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy (PHASE3)
• FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.